Effect of heart failure on catecholamine granule morphology and storage in chromaffin cells

Sushil K Mahata1, Hong Zheng2, Sumana Mahata3

  • 1VA San Diego Healthcare System Metabolic Physiology & Ultrastructural Biology Lab.Department of Medicine, University of California at San Diego, La Jolla, CA, USA.

Insights

Chronic heart failure (HF) activates adrenal glands, increasing catecholamines. This study reveals structural changes in adrenal chromaffin cells, enhancing catecholamine synthesis and release in HF rats.

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology
  • Cell Biology

Background:

  • Sympathoexcitation is a hallmark of chronic heart failure (HF).
  • Adrenal gland activation and elevated circulating catecholamines contribute to HF pathophysiology.
  • The specific in vivo structural and metabolic adaptations of adrenomedullary chromaffin cells in HF remain largely uncharacterized.

Purpose of the Study:

  • To investigate the in vivo structural and metabolic changes in adrenal chromaffin cells in a rat model of chronic heart failure.
  • To elucidate the relationship between sympathoexcitation, adrenal gland overactivation, and catecholamine production in HF.

Main Methods:

  • Chronic heart failure (HF) was induced in male Sprague-Dawley rats via left coronary artery ligation.
  • Cardiac function was assessed using ventricular hemodynamics five weeks post-surgery.
  • Adrenal glands were examined for structural alterations, catecholamine levels, and cellular organelle morphology in HF versus sham-operated rats.

Main Results:

  • HF rats exhibited increased adrenal weight and elevated levels of norepinephrine, epinephrine, and dopamine compared to controls.
  • Ultrastructural analysis revealed increased synaptic vesicles, endoplasmic reticulum, Golgi apparatus, and mitochondria with dilated cristae and glycogen in chromaffin cells of HF rats.
  • These morphological changes suggest enhanced trans-synaptic activation and increased capacity for catecholamine synthesis and release.

Conclusions:

  • Chronic heart failure induces significant structural and metabolic adaptations in adrenal chromaffin cells to support heightened catecholamine production.
  • These cellular adaptations provide a mechanistic link between HF, adrenal overactivation, and elevated plasma catecholamines.
  • The findings offer novel insights into the neurohumoral mechanisms driving cardiovascular dysfunction in chronic heart failure.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Adrenergic Neurons: Neurotransmission01:27

Adrenergic Neurons: Neurotransmission

Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
5.7K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K